The DOI matches its Crossref record; 507 of the 507 references it cites were found in a registry or an index.
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies
Open accessAbstract
The endothelium, a cellular monolayer lining the blood vessel wall, plays a critical role in maintaining multiorgan health and homeostasis. Endothelial functions in health include dynamic maintenance of vascular tone, angiogenesis, hemostasis, and the provision of an antioxidant, anti-inflammatory, and antithrombotic interface. Dysfunction of the vascular endothelium presents with impaired endothelium-dependent vasodilation, heightened oxidative stress, chronic inflammation, leukocyte adhesion and hyperpermeability, and endothelial cell senescence. Recent studies have implicated altered endothelial cell metabolism and endothelial-to-mesenchymal transition as new features of endothelial dysfunction. Endothelial dysfunction is regarded as a hallmark of many diverse human panvascular diseases, including atherosclerosis, hypertension, and diabetes. Endothelial dysfunction has also been implicated in severe coronavirus disease 2019. Many clinically used pharmacotherapies, ranging from traditional lipid-lowering drugs, antihypertensive drugs, and antidiabetic drugs to proprotein convertase subtilisin/kexin type 9 inhibitors and interleukin 1β monoclonal antibodies, counter endothelial dysfunction as part of their clinical benefits. The regulation of endothelial dysfunction by noncoding RNAs has provided novel insights into these newly described regulators of endothelial dysfunction, thus yielding potential new therapeutic approaches. Altogether, a better understanding of the versatile (dys)functions of endothelial cells will not only deepen our comprehension of human diseases but also accelerate effective therapeutic drug discovery. In this review, we provide a timely overview of the multiple layers of endothelial function, describe the consequences and mechanisms of endothelial dysfunction, and identify pathways to effective targeted therapies. Significance Statement The endothelium was initially considered to be a semipermeable biomechanical barrier and gatekeeper of vascular health. In recent decades, a deepened understanding of the biological functions of the endothelium has led to its recognition as a ubiquitous tissue regulating vascular tone, cell behavior, innate immunity, cell-cell interactions, and cell metabolism in the vessel wall. Endothelial dysfunction is the hallmark of cardiovascular, metabolic, and emerging infectious diseases. Pharmacotherapies targeting endothelial dysfunction have potential for treatment of cardiovascular and many other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Shan, H., Guo, D., Zhang, S., Qi, H., Liu, S., Du, Y., He, Y., Wang, B., Xu, M. G., & Yu, X. (2020) · Cell & Bioscience · doi:10.1186/s13578-019-0371-2 · Cited by 34
RetractedWang, J., Li, P., Xu, X., Zhang, B., & Zhang, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00907 · Cited by 34
RetractedZhao, Q., Xu, H., Zhang, L., Liu, L., & Wang, L. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1620248 · Cited by 14
RetractedDing, H., Huang, J., Wu, D., Zhao, J., Huang, J., & Lin, Q. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-19-2472 · Cited by 13
RetractedA pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citationAtherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475 · cited 2×
“Other emerging drugs with therapeutic potential include anticoagulant drugs (Paar et al., 2021), dexamethasone (Horby et al., 2021), canakinumab (an anti–IL-1b monoclonal antibody) (Ucciferri et al., 2020), adrecizumab (an anti-adrenomedullin antibody) (Karakas et al., 2020), and NLRP3 inflammasome…”
BackgroundAntiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Cited by
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,062
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Self-citationEndothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications
Gallo, G., Volpe, M., & Savoia, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.798958 · Cited by 446
“In particular, the delivery through nanoparticles of many clinically used drugs such as antihypertensive agents, statins, antidiabetic drugs and interleukin 1β monoclonal antibodies may represent a potential target for treatment of endothelial dysfunction thus yielding potential new therapeutic approaches (78).”
BackgroundXu, S.-W., Ilyas, I., & Weng, J.-P. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00998-0 · Cited by 440
Self-citationJiang, H., Zhou, Y., Nabavi, S. M., Sahebkar, A., Little, P. J., Xu, S., Weng, J., & Ge, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.925923 · Cited by 323
Self-citationYang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 280
Hypertension, Neurovascular Dysfunction, and Cognitive Impairment
Santisteban, M. M., Iadecola, C., & Carnevale, D. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.18085 · Cited by 279
Mosquera, J. V., Auguste, G., Wong, D., Turner, A. W., Hodonsky, C. J., Alvarez-Yela, A. C., Song, Y., Cheng, Q., Lino Cardenas, C. L., Theofilatos, K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113380 · Cited by 123
Role of the cGAS-STING Pathway in Aging-related Endothelial Dysfunction
Yu, H., Liao, K., Hu, Y., Lv, D., Luo, M., Liu, Q., Huang, L., & Luo, S. (2022) · Aging and disease · doi:10.14336/ad.2022.0316 · Cited by 84
Self-citationZhao, F., He, Y., Zhao, Z., He, J., Huang, H., Ai, K., Liu, L., & Cai, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272133 · Cited by 42
Metadata
- Authors
- Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., Harding, I. C., Ebong, E. E., Cameron, S. J., Stewart, A. G., & Weng, J.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 73
- Issue
- 3
- Pages
- 924-967
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W3165793489
- Cited by
- 1,142
- References
- 507
- FWCI
- 79.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.